To the ability of the @entity3575 patch to control @entity158 in a postoperative @entity235 model, we provided two male beagles with 25-mg/h patches and two with 50-mg/h patches 24 h prior to surgery. Each animal underwent a major abdominal surgical procedure to place three separate catheters with associated vascular access ports. Serum plasma levels of @entity3575 were analyzed at multiple time points throughout the study period. Animals were subjectively assessed for @entity282 by using a Simple Descriptive Scale at regular intervals postoperatively. Other parameters observed and recorded included heart and respiration rates, rectal temperature, appetite, and activity. The @entity3575 patch appeared to adequately control @entity282 in our @entity235 abdominal surgical model. Three animals demonstrated mild @entity158 1 to 2 h postoperatively. Two animals, one from each dose group, showed mild @entity158 8 h postoperatively. Mild @entity158 is commensurate with USDA category C, which encompasses procedures that do not result in more than momentary or slight @entity158 or distress and do not require intervention. At no other time points were any of the animals considered to be in @entity158 . Our study also suggested that increased subcutaneous fat delayed the rate of absorption of @entity3575 . The lower body-weight beagles, which had the 25-mg/h patches, reached reported human serum analgesic levels within 8 h after placement, whereas the heavier beagles with the 50-mg/h patches reached human serum analgesic levels 12 h after placement. @entity3575 concentrations remained at the reported @entity1 analgesic levels in all animals between 2 to 4 h after the patches were removed. Regardless of the dose, decreases in heart rate, respiration rate, and temperature were observed in all four animals 12 h after placing the patches. Issues regarding the regulatory requirements to prevent @entity734 , the side effects and potency of @entity3575 , and the prolonged duration of action as a transdermal system should be addressed by the veterinarian when considering usage of this analgesic method.

@entity282 management using @entity3575 patches in XXXX .

@entity1 :: ('9606', 'Species') :: ['human'] @entity235 :: ('9615', 'Species') :: ['canine'] @entity158 :: ('MESH:D010146', 'Disease') :: ['pain'] @entity282 :: ('MESH:D010149', 'Disease') :: ['postoperative pain'] @entity3575 :: ('MESH:D005283', 'Chemical') :: ['fentanyl', 'Fentanyl'] @entity734 :: ('MESH:D019966', 'Disease') :: ['drug abuse']
@entity235 :: (9615,Species) :: ['dogs']
